We aimed to investigate if serum NfL (sNfL) levels can be a biomarker of disease activity and treatment response in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Here, NEFL is linked to chronic inflammatory demyelinating polyradiculoneuropathy.